Clinical Trial Update: Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating serplulimab in combination with nab-paclitaxel and cisplatin as neoadjuvant therapy for resectable esophageal squamous ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Serplulimab (serplulimab)

Snippet

Sponsor: Yang Jianjun, PhD | Conditions: Esophageal Squamous Cell Carcinoma | Phase 4 | Status: NOT_YET_RECRUITING